Active	Status	Sponsor type	Region	Phase	Filter
3 Active 0 Inactive 3 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Whitman, Emily
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer	Completed	2	79	Europe, Canada, US, RoW	Mirvetuximab soravtansine, MIRV, IMGN853	AbbVie	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	01/24	12/24
Szeligo, Katie
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer	Completed	2	79	Europe, Canada, US, RoW	Mirvetuximab soravtansine, MIRV, IMGN853	AbbVie	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	01/24	12/24
DENALI, NCT05128825: A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Recruiting	2	170	Europe, US, RoW	azenosertib, ZN-c3	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	12/26	06/27

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Whitman, Emily
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer	Completed	2	79	Europe, Canada, US, RoW	Mirvetuximab soravtansine, MIRV, IMGN853	AbbVie	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	01/24	12/24
Szeligo, Katie
PICCOLO, NCT05041257: Mirvetuximab Soravtansine Monotherapy in Platinum-Sensitive Epithelial, Peritoneal, and Fallopian Tube Cancers Oct 2024 - Dec 2024 : Approval for 2L+ FRα +ve PROC Jan 2024 - Jun 2024 : FDA action date for approval for ovarian cancer with high FRAC Jan 2024 - Jun 2024 : sBLA approval for ovarian cancer Jan 2023 - Dec 2023 : ORR data from PICCOLO trial for platinum sensitive ovarian cancer	Completed	2	79	Europe, Canada, US, RoW	Mirvetuximab soravtansine, MIRV, IMGN853	AbbVie	Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer	01/24	12/24
DENALI, NCT05128825: A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Recruiting	2	170	Europe, US, RoW	azenosertib, ZN-c3	K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc	High-Grade Serous Ovarian, Fallopian Tube or Primary Peritoneal Cancer	12/26	06/27